drugset / Trial / NCT00630539
A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg tested earlier in Phase II.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-01
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ospemifene | Other / unclassified | 5 mg | Oral |
| Subject | Ospemifene | Other / unclassified | 15 mg | Oral |
| Subject | Ospemifene | Other / unclassified | 30 mg | Oral |